Rimegepant in Moderate Plaque-type Psoriasis

Inclusion Criteria: * Male or female patients with at least 3% body surface are involved with psoriasis and a PASI score \>5. * Between 18 and 75 years of age. * Documentation of a definite diagnosis of psoriasis by a dermatologist or biopsy. * For women of childbearing potential, a negative urine pregnancy test within 48 hours of randomization. Female subjects should not have attempted to become pregnant in the month prior to exposure to rimegepant and agree not to attempt to become pregnant for 8 weeks after exposure to rimegepant. * A valid form of contraception must be documented for men and women of child-bearing potential. * The two methods for women of childbearing potential should include: * One barrier method (for example, Diaphragm with spermicidal gel, condom with spermicidal gel, cervical caps or intrauterine devices placed for at least four weeks before sexual intercourse); AND * One additional method. The other method could include hormonal contraceptives, or second barrier method as listed above. * The two options for men of childbearing potential should include: * Simultaneous use of male condom, and for the female partner, hormonal contraceptives (for example, birth control pills, implants, patch, depot injection, used since at least 4 weeks) or intra-uterine contraceptive device (placed since at least 4 weeks) before sexual intercourse; OR simultaneous use of male condom, and for the female partner, diaphragm with intravaginally applied s…